SCHEMBL1667490

SCHEMBL1667490

CCCCCCCCCCCCCCCC(=O)c1nc(CC(=O)O)cs1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 1/20 0.66
PDE5A O76074 1/20 0.48
HSD17B10 Q99714 2/20 0.46
GABRA5 P31644 1/20 0.46
GABRB2 P47870 1/20 0.46
CA2 P00918 1/20 0.41
GPR84 Q9NQS5 7/20 0.41
PPARG P37231 7/20 0.41
PPARD Q03181 7/20 0.41
PPARA Q07869 7/20 0.41
HDAC11 Q96DB2 5/20 0.41
TSHR P16473 4/20 0.41
PTPN1 P18031 3/20 0.41
ALDH1A1 P00352 2/20 0.41
TLR2 O60603 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
FABP4 P15090 2/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12548427 0.82 HSD17B10 (0.54) PLA2G4AHSD17B10GABRA5GABRB2ALDH1A1
SCHEMBL1669644 0.79 PLA2G4A (1.00) PLA2G4ACA2GPR84TSHRPTPN1
SCHEMBL15273494 0.78 PLA2G4A (0.67) PLA2G4APDE5ACA2ALDH1A1MEN1
SCHEMBL1000799 0.77 PDE5A (0.79) PDE5AHDAC11TSHRALDH1A1MEN1
SCHEMBL7507762 0.77 GABRA5 (0.49) PLA2G4APDE5AHSD17B10GABRA5GABRB2
SCHEMBL20662506 0.76 HSD17B10 (0.51) PLA2G4AHSD17B10GABRA5GABRB2ALDH1A1
SCHEMBL20429003 0.73 PLA2G4A (0.49) PLA2G4APDE5AHSD17B10GABRA5GABRB2
SCHEMBL13447365 0.73 HSD17B10 (0.51) PDE5AHSD17B10GABRA5GABRB2ALDH1A1
SCHEMBL19156023 0.73 PLA2G4A (0.52) PLA2G4AGPR84PPARA
SCHEMBL1667122 0.72 PLA2G4A (0.71) PLA2G4ACA2ALDH1A1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10370344-B2 2-oxothiazole compounds and method of using same for chronic inflammatory disorders AVEXXIN AS (NO) 2019-08-06 US disclosed
EP-3431084-A1 ANTIINFLAMMATORY 2-OXOTHIAZOLES Avexxin AS (NO) 2019-01-23 EP disclosed
US-20170166539-A1 COMPOUND AVEXXIN AS (NO) 2017-06-15 US disclosed
US-9597318-B2 2-oxothiazole compounds and method of using same for chronic inflammatory disorders AVEXXIN AS (NO) 2017-03-21 US disclosed
EP-2482815-A1 ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES Avexxin AS (NO) 2012-08-08 EP disclosed
US-20110136879-A1 COMPOUND AVEXXIN AS (NO) 2011-06-09 US disclosed
WO-2011039365-A1 ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES AVEXXIN AS (NO) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136879-A1 COMPOUND CBR1, CBR3, CCR1 PLA2G4A 1999/4885PDE5A 4275/4885HSD17B10 515/4885
US-20170166539-A1 COMPOUND CBR1, CBR3, CCR1 PLA2G4A 2011/4885PDE5A 4275/4885HSD17B10 518/4885
US-10370344-B2 2-oxothiazole compounds and method of using same for chronic inflammatory disorders CX3CR1, LTC4S, CBR1 PLA2G4A 1174/4885PDE5A 4749/4885HSD17B10 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.